NextBioMedical Co (389650.KQ) Stock Price

NextBioMedical Co Price

CLOSED
28,350.00
​
Market closed

Revenue has compounded at 64.2% per year over the past 4 years to 16.48 B KRW. NextBioMedical Co's net margin stands at -1.9%, up from -734.1% several years earlier. Analysts set a median price target of 90,780.00 KRW, implying 220.2% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

NextBioMedical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co business model & stock analysis

NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry.

Frequently asked questions about NextBioMedical Co

Analysts currently set an average price target of 99,280.00 KRW for the NextBioMedical Co stock (median: 90,780.00 KRW), implying +250.2 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the NextBioMedical Co stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect NextBioMedical Co to generate revenue of 23.20 B KRW and earnings per share of -349.26 KRW.

Converted at the current exchange rate, the NextBioMedical Co share trades at 18.88 EUR (28,350.00 KRW).

The expected revenue of NextBioMedical Co is 23.20 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of NextBioMedical Co is -2.84 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of NextBioMedical Co is currently -81.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the NextBioMedical Co stock.

The price-to-sales ratio (P/S) of NextBioMedical Co is currently 9.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the NextBioMedical Co stock.

The Eulerpool Quality Score for NextBioMedical Co is 3/10.

The ISIN of NextBioMedical Co is KR7389650003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of NextBioMedical Co is 389650.KQ. The ticker symbol is used to trade NextBioMedical Co shares on the stock exchange.

Fair ValueTerminal
28,917.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Aug 20, 2024
ISIN
KR7389650003
Cusip
Y6S6JG127
Market capitalization
229.26 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-81.17
P/Ee 2027
18.82
P/Se
9.93
EV/EBIT
—
P/B Ratio
4.77
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-0.63 %
Last updated Nov 11, 2026, 5:39 AM

NextBioMedical Co Peer Group